Acebutolol and Immediate Release Melatonin in Treatment of Smith-Magenis Syndrome

Benjamin J. Wheeler, Barry J. Taylor, Kirsten Simonsen, David M. Reith


Sleep disturbance occurs in Smith-Magenis syndrome (SMS) as part of the phenotype. It appears that this disturbance lies primarily in an inversion of the circadian rhythm of melatonin. We assessed whether the use of melatonin and acebutolol together would benefit a patient with SMS with regard to sleep and behavior. Our patient entered a four-way crossover, double-blind, double dummy, placebo-controlled n-of-1 trial, using immediate release melatonin, acebutolol and placebo. The duration of the study was 24 consecutive nights. The primary outcome measure was total nocturnal sleep. Placebo/placebo showed the longest total duration of sleep, 10.62 hours (95% CI: 9.88 - 11.36) as compared to melatonin and acebutolol together with 10.25 (95% CI: 9.40 - 11.11). There were no significant differences found between the secondary outcome measures in particular behavior or global satisfaction. Our results suggest there is no benefit to sleep or subsequent behavior from adding acebutolol and/or immediate release melatonin in patients with SMS.

J Med Cases. 2015;6(4):176-178


Smith-Magenis syndrome; Melatonin; Acebutolol; Clinical trial

Full Text: HTML PDF

Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics


World Journal of Oncology

Gastroenterology Research

Journal of Hematology


Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity


Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research


Journal of Neurology Research

International Journal of Clinical Pediatrics



Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website:   editorial contact:
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.